Regor to Speak at Goldman Sachs 45th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 5, 2024 - Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 12. The company's Founder and CEO, Dr. Xiayang Qiu, will represent Regor Therapeutics in a scheduled session at 11:20 am Eastern Time.

Overview of Regor Therapeutics Group

Established in 2018 by a team of seasoned scientists, Regor Therapeutics Group ("Regor") is marked by a substantial track record in drug discovery and leadership within the pharmaceutical industry. The company leverages its proprietary technology, rCARD™ (Computer Accelerated Rational Discovery), which has enabled the completion of eight preclinical candidates (PCCs) and the filing of five Investigational New Drug (IND) applications. This achievement underscores the efficiency and innovation within Regor's discovery ecosystem, dedicated to accelerating the development of groundbreaking therapeutic agents.

Regor's internal pipeline is robust, focusing on key therapeutic areas such as metabolism, oncology, and auto-immunity. Among its leading assets are:

1. RGT-075: An orally bioavailable small molecule GLP1R full agonist, poised to set new standards in treating obesity and related conditions.
2. RGT-419B: A unique CDK4+ inhibitor, demonstrating remarkable efficacy as a single agent in patients with refractory ER+/HER2- breast cancer.

Mission and Vision

Regor Therapeutics is committed to achieving excellence in pharmaceutical research and maintaining a competitive global presence. The company aims to establish a world-class innovation engine, fostering a culture rooted in scientific excellence and teamwork. This culture emphasizes results, accountability, and shared success, propelling Regor to the forefront of biopharmaceutical innovation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!